#drug-pricing

#drug-pricing

Hikma's generic Vascepa, with its "skinny label," poses a challenge for patent protection, potentially undermining the incentives for innovation in the pharmaceutical industry.

Senate Democrats and the Biden administration abandoned plans to cap drug prices based on payments in other wealthy nations during negotiations to empower Medicare's negotiation capabilities.

Trump's executive order asks drugmakers to voluntarily lower pharmaceutical costs for U.S. consumers, but lacks a definitive mechanism for enforcing these reductions.

"While Senator Lee agreed that minimizing sham petitions would be beneficial, he argued that legislating such a presumption would turn a company's day in court into 'a blunted opportunity for due process.'"},{